50 February / March 2017 Column: 50 x 5.0 mm ID


Equilibration buffer: 20 mM citric acid-NaOH buffer (pH 5.3 or 6.0) Elution buffer: Flow rate:


Temperature: Detection: Sample:


Equilibration buffer containing 0.5 M NaCl 200 - 800 cm/hr (0.66-2.62 mL/min) ambient (25°C) UV at 280nm


1.5 mg/mL human polyclonal Adalimumab in equilibration buffer


Influence of Linear Velocity


BioPro SmartSep maintains higher binding capacity values over a wider range of linear velocity. This will increase product throughput for the purification work without loss of efficiency.


APPLICATION NOTE


Influence of Salt Concentration pH


NaCI concentration Conductivity


BioPro SmartSep S30 particles Influence of pH pH BioPro SmartSep S30


Tosoh TSKgel SP-3PW (30 µm) GE Source 30S (30 µm)


DBC (mg/mL-resin, 10% breakthrough) pH 5.3 110 61 58


pH 6.0 103 64 58


BioPro SmartSep S30


Tosoh TSKgel SP-3PW (30 µm) GE Source 30S (30 µm)


DBC (mg/mL-resin, 10% breathrough) 5.3


0 mM 25 mM


97 55 49


50 mM


1.36 mS/cm 4.14 mS/cm 6.8 mS/cm 107 64 58


50 27 19


BioPro SmartSep has higher salt concentration tolerance. This simplifies the desalting pro¬cess after Protein A chromatography and will help to shorten the production process.


Conclusions


High binding capacities are achieved regardless of elution of pH. Therefore, milder eluting conditions for Adalimumab can be selected.


BioPro SmartSep materials meet the highest demands for the purification of monoclonal antibodies. High binding capacity is achieved regardless of elution of pH, linear velocity or salt concentration. This allows purification processes to be carried out more efficiently.


Linear velocity BioPro SmartSep S30


Tosoh TSKgel SP-3PW (30 µm) GE Source 30S (30 µm)


DBC (mg/mL-resin, 10% breakthrough)


200 cm/hr 400 cm/hr 800 cm/hr 110 61 58


93 42 41


84 26 23


• Milder eluting conditions can be selected • Higher throughput at stable efficiencies • Simplification of desalting processes for shorter processes


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60